Biotech & PharmaSix FDA Oncology Decisions Due in 2026 — ADCs, Cell Therapies, and Checkpoint Inhibitors Face Global Catalyst CalendarSalvado•Jun 19, 2026
Pharmaceuticals & BiotechFDA's H2 2026 Drug Decision Cluster Triggers Global Biotech Repricing in ADCs and Cell TherapiesSalvado•Jun 17, 2026
Biotech & PharmaGlobal ADC Combination Race Peaks in 2026–2027, Compressing Binary Risk Across Three ContinentsSalvado•May 27, 2026
Pharmaceuticals & BiotechVepdegestrant's 5-Month PFS Anchors Cross-Border Oncology Deals as 2026 PDUFA Cluster Reshapes Global Drug ValuationsSalvado•May 17, 2026
Biotechnology & PharmaAmgen Merges R&D and AI Leadership as Global Pharma Embeds Generative AI Into Research StrategySalvado•Apr 30, 2026
BiotechGlobal Biotech Valuations Rise as $120B Oncology Pipeline Targets 2026-2027 FDA ApprovalsSalvado•Apr 18, 2026
biotechnologyChina's Kelun-Biotech Fields 30+ Oncology Candidates in Global ADC Race Against Pfizer, RegeneronSalvado•Mar 26, 2026
BiotechCardiff Oncology's $60M Cash Reserve Gives Five Quarters Before Funding CrisisViaNews Editorial Team•Mar 7, 2026
biotechnologyCardiff Oncology's $500M+ valuation at risk as cancer trial targeting 40-50% of colorectal cases nears Q1 2026 data releaseViaNews Editorial Team•Mar 7, 2026
pharmaceuticalsBiotech Kyntra Bio Risks 60-80% Wipeout as Single Cancer Drug FG-3246 Faces Trial VerdictViaNews Editorial Team•Feb 26, 2026
Healthcare & PharmaGlobal Pharma Giants Race to Dominate Oncology: A Worldwide M&A Wave Reshapes Cancer TreatmentViaNews Editorial Team•Feb 17, 2026
AnalysisFour Immunotherapy Companies Race Toward 2026 Launches as Next-Generation Cancer Treatments Near MarketViaNews Editorial Team•Feb 15, 2026
AnalysisMajor Drugmakers Reshape Cancer Treatment Through Billion-Dollar Acquisitions, FDA ApprovalsViaNews Editorial Team•Feb 15, 2026
